Ultimovacs ASA

ULTI

NO0010851603

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-30 am EDT			5-day change	1st Jan Change
6.98 ^NOK	+0.29%		-11.65%	-94.32%

Apr. 17	Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	MT
Apr. 17	Transcript : Ultimovacs ASA - Special Call

Ultimovacs ASA - Mandatory trade notification and disclosure of holding

March 08, 2024 at 02:15 am EST

Oslo, 7 March 2024: CGS Holding AS, Helene Sundt AS and Sundt AS have today sold
a total of 2,231,255 shares in Ultimovacs ASA, following which they collectively
own 420,000 shares in Ultimovacs ASA, representing ca. 1.22% of the issued
shares and votes in the company. Please refer to the attached forms for further
details.

This disclosure is made pursuant to the Market Abuse Regulation article 19 and
sections 4-2 and 5-12 of the Norwegian Securities Trading Act.

Click here for more information

Latest news about Ultimovacs ASA

Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	Apr. 17	MT
Transcript : Ultimovacs ASA - Special Call	Apr. 17
Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program	Apr. 16	CI
Transcript : Ultimovacs ASA - Special Call	Mar. 07
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma	Mar. 07	CI
Ultimovacs Wins Orphan Drug Designation in Europe for Cancer Vaccine	Feb. 19	MT
Transcript : Ultimovacs ASA, Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
Ultimovacs ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Ultimovacs ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Ultimovacs' Cancer Vaccine Obtains Fast-Track Designation from US FDA	Feb. 05	MT
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma	Feb. 05	CI
Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma	Jan. 16	CI
Ultimovacs ASA Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint	Dec. 18	CI
Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors	Nov. 28	CI
Ultimovacs ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Transcript : Ultimovacs ASA, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Ultimovacs Finalizes Patient Recruitment for Supplementary Study of Cancer Vaccine	Nov. 02	MT
Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma	Nov. 02	CI
Transcript : Ultimovacs ASA - Special Call	23-10-31
Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024	23-10-31	CI
Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid	23-10-23	CI
Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)	23-10-17	CI
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine	23-10-12	CI
Ultimovacs Secures US FDA's Orphan Drug Tag for Cancer Vaccine	23-10-09	MT
Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma	23-10-09	CI

Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

6.98 NOK

Average target price

6.5 NOK

Spread / Average Target

-6.88%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ULTIMOVACS ASA	-94.32%	21.69M
IQVIA HOLDINGS INC.	+1.72%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+7.59%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.76%	18.2B
MEDPACE HOLDINGS, INC.	+29.18%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.58%	11.76B
UNITED THERAPEUTICS CORPORATION	+15.22%	10.4B
BIO-TECHNE CORPORATION	-3.97%	9.94B

Other Biotechnology & Medical Research

Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Ultimovacs ASA - Mandatory trade notification and disclosure of holding

Latest news about Ultimovacs ASA

Chart Ultimovacs ASA

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research